10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45Gy (1.5Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)—A multicenter phase-II trial (CISTAXOL)-Reference-Cited by-同舟云学术

10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45Gy (1.5Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)—A multicenter phase-II trial (CISTAXOL)

Published:2013-10 Issue:1 Volume:82 Page:83-89
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Eberhardt Wilfried Ernst Erich,Gauler Thomas Christoph,LePechoux Cecile,Stamatis Georgios,Bildat Stephan,Krbek Thomas,Welter Stefan,Grunenwald Dominique,Fischer Berthold,Rodrigo Hepp de los Rios,Theegarten Dirk,Le Chevalier Thierry,Seeber Siegfried,Stuschke Martin,Poettgen Christoph

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference40 articles.

1. European cancer mortality predictions for the year 2012;Malvezzi;Ann Oncol,2012

2. Cancer statistics, 2012;Siegel;CA Cancer J Clin,2012

3. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours;Goldstraw;J Thorac Oncol,2007

4. FDG-PET in the locoregional lymph node staging of non-small cell lung cancer. A comprehensive review of the leuven lung cancer group experience;Vansteenkiste;Clin Positron Imaging,1999

5. Nonsurgical staging of the mediastinum: EBUS and EUS;Herth;Semin Respir Crit Care Med,2011

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms;Pneumologie;2023-10

2. Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options;Current Oncology;2023-03-07

3. Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials;ESMO Open;2022-04

4. A randomized, multicenter phase II study comparing efficacy, safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer;Therapeutic Advances in Medical Oncology;2021-01

5. Prognostic factors for pN2 non-small cell lung cancer: a comprehensive evidence from 73 studies involving 23,772 patients*;Oncology and Translational Medicine;2020-04